Brief: Verve Therapeutics Reports New Preclinical Data Of ANGPTL3 Gene With VERVE-201

Verve Therapeutics

03/03/2023 11:46

March 3 (Reuters) - Verve Therapeutics Inc  VERV.O :
    * VERVE THERAPEUTICS REPORTS NEW PRECLINICAL DATA
DEMONSTRATING
POTENT AND DURABLE EDITING OF ANGPTL3 GENE WITH VERVE-201 IN
WILD-TYPE AND LDLR-DEFICIENT NON-HUMAN PRIMATES
    * VERVE THERAPEUTICS INC: DATA SUPPORTS ADVANCEMENT OF DRUG
CANDIDATE TOWARD CLINICAL DEVELOPMENT FOR HOMOZYGOUS FAMILIAL
HYPERCHOLESTEROLEMIA
    * VERVE THERAPEUTICS INC: CONTINUE TO PROGRESS VERVE-201
TOWARD
CLINICAL DEVELOPMENT, WITH PLANS TO INITIATE A FIRST-IN-HUMAN
CLINICAL TRIAL IN 2024

Source text for Eikon:  ID:nGNX1qHwJ1 
Further company coverage:  VERV.O 

 ((Reuters.Briefs@thomsonreuters.com;))